

6-MONTH  
REPORT

12-MONTH  
REPORT

18-MONTH  
REPORT

24-MONTH  
REPORT

2020

2021

# PANDEMIC INFLUENZA PREPAREDNESS FRAMEWORK

1 January –  
30 June  
2020

## PROGRESS REPORT



World Health  
Organization

Pandemic Influenza Preparedness Framework: progress report, 1 January - 30 June 2020.

ISBN 978-92-4-001265-3 (electronic version)

ISBN 978-92-4-001266-0 (print version)

© World Health Organization 2020.

**Some rights reserved.** This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** Pandemic Influenza Preparedness Framework: progress report, 1 January - 30 June 2020. Geneva: World Health Organization; 2020. Licence: [CC BY-NC-SA 3.0 IGO](#).

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

# INTRODUCTION

The **Pandemic Influenza Preparedness (PIP) Framework** is an innovative public health instrument that brings together Member States, industry, other stakeholders and WHO to implement a global approach to pandemic influenza preparedness and response. The key goals include: to improve and strengthen the sharing of influenza viruses with human pandemic potential through the WHO Global Influenza Surveillance and Response System (GISRS), and to increase the access of developing countries to vaccines and other pandemic response supplies.

The Framework includes a benefit-sharing mechanism called the Partnership Contribution (PC). The PC is collected as an annual cash contribution from influenza vaccine, diagnostic, and pharmaceutical manufacturers that use GISRS. Funds are allocated for: **(a)** pandemic preparedness capacity building; **(b)** response activities during the time of an influenza pandemic; and **(c)** PIP Secretariat for the management and implementation of the Framework.

For pandemic preparedness capacity building, activities are implemented according to six outputs under one outcome in the *High Level Implementation Plan (HLIP) II 2018-2023*. The technical and financial investments of countries and other partners, including GISRS, play a critical role in advancing pandemic preparedness alongside PC investments. Collectively, resources are used to strengthen pandemic preparedness systems, knowledge and capacities. We thank countries and partners for their important role and contribution. The progress made and successes achieved are a result of joint collaboration on common objectives. The PIP PC funding model is described in *HLIP II*, Section 6.

This reporting format addresses the recommendation from the 2016 PIP Review that WHO develop progress reports that present overall success metrics and infographics to illustrate progress in PIP Framework implementation. A progress report is published four times a biennium, and covers technical and financial implementation for HLIP II, as well as the PIP Secretariat. Milestones are reported every six months and indicators are reported yearly. All data are presented cumulatively from the beginning of each biennium, in this case, 1 January 2020.

For financial implementation, progress is reported against biennial workplan allocations. Figures presented exclude WHO Programme Support Costs (PSC) unless otherwise stated. For the mid-year reports, income, expenditures and encumbrances are presented, and are based on WHO's financial tracking system (GSM). For annual and biennial reports, income and expenditures are presented, in line with the yearly WHO Interim Certified Financial Statement.

This issue of the PIP progress report was developed as the world continues to respond to the coronavirus disease 2019 (COVID-19) pandemic. Despite the many challenges brought on by this global crisis, much was nonetheless achieved to continue the work to prepare for the next influenza pandemic, and readers will be able to learn about some of the happenings on the ground in a new section entitled "Stories from the field".

Many staff across WHO Clusters and Departments in all Major Offices support the implementation of the PIP Framework. Without their work, dedication and collaboration, there would be no progress to report on. We extend our sincere thanks to these staff for their invaluable work.

The report is structured as a series of infographics as follows:

<b>PIP Framework implementation overview</b>	<b><u>pages 5 - 7</u></b>
<b>Technical and financial implementation progress</b>	<b><u>pages 8 - 18</u></b>
<b>Stories from the field</b>	<b><u>pages 19 - 28</u></b>

For previous reports, see [https://www.who.int/influenza/pip/partnership\\_contribution/en/](https://www.who.int/influenza/pip/partnership_contribution/en/)


# ACRONYMS & ABBREVIATIONS

<b>AFRO</b>	WHO Regional Office for Africa	<b>IVTM</b>	National Influenza Centre
<b>AMR</b>	WHO Region of the Americas	<b>L&amp;S</b>	National Immunization Technical Advisory Groups
<b>BM</b>	Biological Material	<b>NIC</b>	Influenza Virus Traceability Mechanism
<b>BOD</b>	Burden of Disease	<b>NITAG</b>	Laboratory and Surveillance Capacity Building
<b>CC</b>	Collaborating Centre	<b>NRA</b>	National Regulatory Authority
<b>CVV</b>	Candidate Vaccine Virus	<b>NVDP</b>	National Vaccine Deployment Plan
<b>DEP</b>	Planning for Deployment	<b>PAHO</b>	Pan American Health Organization
<b>DG</b>	Director-General	<b>PC</b>	Partnership Contribution
<b>EMR</b>	WHO Eastern Mediterranean Region	<b>PCR</b>	Polymerase Chain Reaction
<b>EMRO</b>	WHO Regional Office for the Eastern Mediterranean	<b>PIP</b>	Pandemic Influenza Preparedness
<b>EQAP</b>	External Quality Assessment Programme	<b>PISA</b>	Pandemic Influenza Severity Assessment
<b>EUR</b>	WHO European Region	<b>PSC</b>	Programme Support Costs
<b>FDA</b>	Food and Drug Authority	<b>PSS</b>	Pandemic Special Studies
<b>FETP</b>	Field Epidemiology Training Program	<b>RCCE</b>	Risk Communications and Community Engagement
<b>FoRCCE</b>	Foundations of Risk Communications and Community Engagement	<b>REG</b>	Regulatory Capacity Building
<b>GBT</b>	Global Benchmarking Tool	<b>SARI</b>	Severe Acute Respiratory Illness
<b>GISRS</b>	Global Influenza Surveillance and Response System	<b>SEAR</b>	WHO South-East Asia Region
<b>HAI</b>	Human Animal Interface	<b>SFP</b>	Shipping Fund Project
<b>HLIP</b>	High-Level Implementation Plan	<b>SMTA2</b>	Standard Material Transfer Agreement 2
<b>IDP</b>	Institutional Development Plan	<b>UNICEF</b>	United Nations Children's Fund
<b>IHR</b>	International Health Regulations	<b>US CDC</b>	United States Centers for Disease Control and Prevention
<b>ILI</b>	Influenza-like-illness	<b>VCM</b>	Vaccine Composition Meeting
<b>IPPP</b>	Influenza Pandemic Preparedness Planning	<b>WER</b>	Weekly Epidemiological Record
<b>ISST</b>	Infectious Substances Shipping Training	<b>WHA</b>	World Health Assembly
<b>IVPP</b>	Influenza Virus with Pandemic Potential	<b>WHO</b>	World Health Organization

# IMPLEMENTATION OVERVIEW

## PIP PC collection (As of 30 June 2020)

### PERCENTAGE OF TOTAL PC RECEIVED FROM CONTRIBUTORS




<sup>a</sup> In 2012, contributions were made voluntarily.

<sup>b</sup> Figure includes PSC. PC collection for previous unpaid contributions and 2020 invoices is in process. Invoices for 2020 were issued on 25 June 2020. The figure does not include interest earned on Response Funds of \$2.5M in 2018-19.

## PIP PC financial implementation (As of 30 June 2020)

### PREPAREDNESS

2020-2021 BIENNIAL BUDGET: **\$31.4M** FUNDED: **\$16.7M** IMPLEMENTED: **\$5.4M**



### PIP SECRETARIAT

BIENNIAL BUDGET: **\$5.8M**

FUNDED: **\$3.3M**

IMPLEMENTED: **\$832K**

### RESPONSE

TOTAL IN RESERVE  
(WITH PSC & \$2.5M  
INTEREST EARNED IN  
2018-19): **\$56M**

### LEGEND

Biennial budget  
Funded  
Implemented

## PIP Framework outcome indicators

### OUTCOME

Improved global pandemic influenza preparedness and response through the implementation of the PIP Framework

Indicator	2019 Baseline	2020 Status	2021 Target
% of Member States with zoonotic influenza cases sharing IVPPs with GISRS (N=7)	57%	Pending (Indicators are reported annually)	N/A
% of PC recipient Member States reporting to FluNet (sustainability indicator, N=37)	97%		≥85%
% of PC recipient Member States reporting to FluID (N=37)	81%		70%
% of Member States with BOD estimates considered by NITAG or other decision-making bodies (N=38)	11%		40%
No. of PC recipient Member States that have implemented regulatory approach (N=48)	22		23
% of PC recipient Member States that developed or updated a pandemic influenza preparedness plan (N=40)	65%		75%
% of influenza vaccine & antiviral manufacturers that concluded an SMTA2 (N=32)	41%		50%
% of Partnership Contributions received in the year of invoice (N=\$28M)	58%		100%

## PIP Biological Materials<sup>a</sup> shared

PIP BMs RECORDED IN IVTM



FROM 1 JANUARY TO  
30 JUNE 2020:

**55**

VIRUS SUBTYPES RECORDED:  
A(H5N1), A(H9N2), A(H3N2)v,  
A(H1N1)v, A(H1N2)v, A(H5N6)



TOTAL SINCE 1 DECEMBER 2012:

**1263**

PIP BMs RECORDED

<sup>a</sup> For definition of 'PIP Biological Materials', see PIP Framework Section 4.1

## SMTA2: SECURING PRODUCTS FOR PANDEMIC RESPONSE

SMTA2 WITH VACCINE MANUFACTURERS SINCE 2013

Large / multi-national  
manufacturers

**>75M**

pandemic production



Medium-sized  
manufacturers

**>5M and <75M**

pandemic production



Small  
manufacturers

**<5M**

pandemic production

NEW: 1 additional SMTA2  
signed since 1 January 2020



**>400M**

DOSES SECURED FOR  
PANDEMIC RESPONSE

SMTA2 WITH ANTIVIRAL AND DIAGNOSTIC MANUFACTURERS & ACADEMIC AND RESEARCH INSTITUTIONS



**10M**

TREATMENT COURSES  
OF ANTIVIRALS



**250,000**

DIAGNOSTIC KITS



**25M**

SYRINGES



**73**

SMTA2 WITH ACADEMIC  
& RESEARCH INSTITUTIONS

NEW: 3 additional  
SMTA2 signed since  
1 January 2020



**29**

BENEFIT-SHARING  
OFFERS FROM ACADEMIC  
& RESEARCH INSTITUTIONS

## PIP Framework governance

Since January 2020, the world has been responding to the COVID-19 pandemic. This has had an impact on implementation of the PIP Framework, but progress was nonetheless made to carry forward Member State requests under Decision

WHA72(12). Through an iterative process, the Secretariat developed and shared the following: 1) report on influenza virus sharing (OP1(a)); 2) report on legislative and regulatory measures related to influenza (OP1(b)); 3) report on the search engine, raising awareness of the PIP Framework, and new technologies (OP1(c), (d) and (e)). In addition, the Secretariat took steps to implement the amendment to footnote 1 of the model SMTA2 found at Annex 1 of the Framework by modifying the SMTA2 template and developing the process to amend all agreements signed to date.



# IMPLEMENTATION PROGRESS

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_24336](https://www.yunbaogao.cn/report/index/report?reportId=5_24336)

